Analysts UBS maintain buy rating on MBX Biosciences (MBX) with a target price of $60, indicating nearly 50% upside
MBX Biosciences has more than tripled over the past year, but there's likely more to go as the biotech makes progress on developing a new GLP-1 treatment, according to UBS.